
NRG Therapeutics has successfully closed an oversubscribed $67 million Series B financing round. The UK-based neuroscience company plans to use these funds to advance its novel approach targeting mitochondrial dysfunction in neurodegenerative diseases.
SV Health Investors' Dementia Discovery Fund led the round, bringing together several prominent life science investors. New backers include British Business Bank, M Ventures, Novartis Venture Fund, and Criteria Bio Ventures. Existing investors Omega Funds and Brandon Capital also participated, while founding investor Parkinson's UK continues its support through the Parkinson's Virtual Biotech.
The funding addresses significant unmet medical needs in neurodegenerative disorders. Parkinson's disease affects millions worldwide, with global prevalence expected to double by 2050. Current treatments only provide temporary symptom relief without slowing disease progression.
ALS, also known as motor neurone disease, presents an even more urgent challenge as a rare but rapidly progressing condition. While the FDA approved Qalsody in 2023 for a specific genetic form of ALS, most patients with the sporadic version still lack effective treatment options.
The Series B proceeds will primarily fund NRG's journey toward clinical proof of concept in ALS/MND using their lead compound, NRG5051. The company also plans to generate meaningful clinical data in Parkinson's patients through a Phase 1b study.
NRG5051 represents a first-in-class oral inhibitor targeting the mitochondrial permeability transition pore (mPTP). The drug has completed IND-enabling studies and is scheduled to enter first-in-human trials in early 2026. Preclinical results show the compound provides significant neuroprotection and reduces neuroinflammation in both Parkinson's and ALS models.
Founded as a private neuroscience company, NRG Therapeutics focuses on mitochondrial dysfunction as a key driver of neurodegeneration. The company operates from the Stevenage Bioscience Catalyst in the UK, where it has developed its understanding of mPTP biology.
Co-founder and CEO Neil Miller brings experience in drug development for neurological conditions. Under his leadership, NRG has identified a novel regulator of the mPTP that enables small molecule inhibition. "Developing new drugs to treat neurological diseases is very challenging but is receiving increased interest given the high unmet medical need and growing prevalence in aging populations," Miller explained.
The company's approach targets mitochondria, cellular powerhouses that are particularly important for energy-hungry neurons. In Parkinson's disease, substantia nigra neurons face high energy demands, while motor neurons in ALS show similar vulnerability. Pathological proteins like α-synuclein in Parkinson's and TDP-43 in ALS damage mitochondria, contributing to disease progression.
The investment round reflects growing confidence in NRG's scientific platform and clinical potential. Laurence Barker, Partner leading the Dementia Discovery Fund at SV Health Investors, highlighted the strength of preclinical data supporting NRG's approach.
"The strength and breadth of NRG's pre-clinical data gives us real confidence that NRG's approach could halt or significantly slow disease progression across multiple neurodegenerative diseases," Barker noted. Francesco Draetta from Omega Funds praised the company's progress over three years, particularly in advancing both drug development and scientific understanding of mitochondrial dysfunction.
The funding brings new board members including Laurence Barker, Emma Johnson from British Business Bank, Charlotte Kremers from M Ventures, and Florian Muellershausen from Novartis Venture Fund. Professor David Dexter, Director of Research at Parkinson's UK, joins as a special advisor on Parkinson's programs.

